title: [Nephrotic syndrome and Gram-negative sepsis in a patient with strongyloidiasis: a case report].
abstract: Strongyloidiasis is caused by a small intestinal nematode with a complex life cycle. In Italy the infection is endemic in rural areas of the Po Valley. The clinical syndrome of S. stercoralis encompasses a broad spectrum of symptoms and signs and, in the immunocompromised host, larvae can migrate to different organs and tissues. Also immune response seems to play a role in the pathogenesis of the disease. We report a case of strongyloidiasis complicated by Gram-negative sepsis and nephrotic syndrome in an immigrant from South America with a normal immune response. Whereas sepsis cleared up quickly, parasitic clearance was obtained only after treatment with ivermectin and nephrotic syndrome was still present three months after the end of treatment.
authors.affiliation: U.O. di Nefrologia e Dialisi - A.R.N.A.S. Civico- Palermo, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: Rotolo
authors.forename: Francesco
authors.initials: F
authors.lastname: Scarlata
authors.forename: Salvatore
authors.initials: S
authors.lastname: Giordano
authors.forename: Calogera
authors.initials: C
authors.lastname: Tortorici
authors.forename: Luisa
authors.initials: L
authors.lastname: Bono
authors.forename: Mario
authors.initials: M
authors.lastname: Coglitore
authors.forename: Cesare
authors.initials: C
authors.lastname: Faraci
authors.forename: Laura
authors.initials: L
authors.lastname: Infurnari
authors.forename: Raffaella
authors.initials: R
authors.lastname: Rubino
authors.forename: Amelia
authors.initials: A
authors.lastname: Romano
mesh_terms: D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications*; D004484:Ecuador / Q000208:ethnology; D019353:Endemic Diseases; D004927:Escherichia coli Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007121:Immunocompetence; D007558:Italy / Q000453:epidemiology; D007559:Ivermectin / Q000627:therapeutic use; D007814:Larva; D008297:Male; D009402:Nephrosis, Lipoid / Q000209:etiology; D009404:Nephrotic Syndrome / Q000209:etiology*; D011241:Prednisone / Q000627:therapeutic use; D017171:Strongyloides stercoralis / Q000254:growth & development; D013322:Strongyloidiasis / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D007559:Ivermectin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015766:Albendazole; D011241:Prednisone